Quantification of relevance of quality of life assessment for patients with cognitive impairment: The suitability indices

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Baumstarck, Karine ^a   Boucekine, Mohamed ^a   Boyer, Laurent ^a   Aghababian, Valérie ^b   Parola, Nathalie ^c   Reuter, Françoise ^d   Loundou, Anderson ^a   Lançon, Christophe ^c   Pelletier, Jean ^d   Auquier, Pascal ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b University of Provence Aix Marseille University   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Cognitive impairment; Multiple sclerosis; MusiQoL; Quality of life; Reliability; Schizophrenia; SQoL; Validity

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE;

ADULT; ARTICLE; ATTENTION; CLINICAL PRACTICE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DSM-IV; EXTERNAL VALIDITY; FACTORIAL ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RELIABILITY; SCHIZOPHRENIA; SELF CONCEPT; SELF REPORT; VALIDATION STUDY; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; PSYCHOLOGY;

ADULT; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; SCHIZOPHRENIA; SELF REPORT;

EID: 84899113113     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-78     Document Type: Article

References (59)

1. Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics 2001, 19(2):187-195. 10.2165/00019053-200119020-00005, 11284382.
2. Bottomley A, Jones D, Claassens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer 2009, 45(3):347-353. 10.1016/j.ejca.2008.09.032, 19013787.
3. Greenhalgh J, Long AF, Flynn R. The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory?. Soc Sci Med 2005, 60(4):833-843. 10.1016/j.socscimed.2004.06.022, 15571900.
4. Awad AG. Quality-of-life assessment in schizophrenia: the unfulfilled promise. Expert Rev Pharmacoecon Outcomes Res 2011, 11(5):491-493. 10.1586/erp.11.61, 21958091.
5. Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J. General health status measures for people with cognitive impairment: learning disability and acquired brain injury. Health Technol Assess 2001, 5(6):1-100.
6. Gold SM, Schulz H, Monch A, Schulz KH, Heesen C. Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler 2003, 9(4):404-410. 10.1191/1352458503ms927oa, 12926847.
7. Marrie RA, Miller DM, Chelune GJ, Cohen JA. Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. Mult Scler 2003, 9(6):621-626. 10.1191/1352458503ms971oa, 14664477.
8. Nishiyama T, Ozaki N. Measurement limit of quality-of-life questionnaires in psychiatric settings. Qual Life Res 2010, 19(1):25-30. 10.1007/s11136-009-9556-1, 19936965.
9. Voruganti L, Heslegrave R, Awad AG, Seeman MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998, 28(1):165-172. 10.1017/S0033291797005874, 9483693.
10. Baro E, Ferrer M, Vazquez O, Miralles R, Pont A, Esperanza A, Cervera AM, Alonso J. Using the Nottingham Health Profile (NHP) among older adult inpatients with varying cognitive function. Qual Life Res 2006, 15(4):575-585. 10.1007/s11136-005-3691-0, 16688491.
11. Bureau-Chalot F, Novella JL, Jolly D, Ankri J, Guillemin F, Blanchard F. Feasibility, acceptability and internal consistency reliability of the nottingham health profile in dementia patients. Gerontology 2002, 48(4):220-225. 10.1159/000058354, 12053111.
12. DePalma JA. Measuring quality of life of patients of traumatic brain injury. Crit Care Nurs Q 2001, 23(4):42-51. 10.1097/00002727-200102000-00004, 11852949.
13. Goverover Y, Chiaravalloti N, DeLuca J. The relationship between self-awareness of neurobehavioral symptoms, cognitive functioning, and emotional symptoms in multiple sclerosis. Mult Scler 2005, 11(2):203-212. 10.1191/1352458505ms1153oa, 15794396.
14. Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004, 10(6):675-678. 10.1191/1352458504ms1098oa, 15584493.
15. Baumstarck K, Reuter F, Boucekine M, Aghababian V, Klemina I, Loundou A, Pelletier J, Auquier P. Relevance of quality of life assessment for multiple sclerosis patients with memory impairment. Plos ONE 2012, 7(12):e50056. 10.1371/journal.pone.0050056, 3519834, 23239975.
16. Baumstarck K, Boucekine M, Klemina I, Reuter F, Aghababian V, Loundou A, Pelletier J, Auquier P. What is the relevance of quality of life assessment for patients with attention impairment?. Health Qual Life Outcomes 2013, 11:70. 10.1186/1477-7525-11-70, 3640938, 23618058.
17. Baumstarck K, Boyer L, Boucekine M, Aghababian V, Parola N, Lancon C, Auquier P. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr Res 2013, 147(1):58-67. 10.1016/j.schres.2013.03.008, 23566495.
18. Juniper EF, Guyatt GH, Mesbah M, Ravaud P. Quality of life and pharmacoeconomics in clinical trials 1996, Philadelphia: Lippincott-Raven.
19. Nunnaly JC, Bernstein IC. Psychometric theory 1994, New York: Mc Graw-Hill.
20. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006, 245(1-2):41-46.
21. Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, Pelletier J. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007, 13(1):124-127. 10.1177/1352458506071196, 17294621.
22. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000, 14(1):1-21.
23. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004, 72(1):41-51. 10.1016/j.schres.2004.09.009, 15531406.
24. Agartz I, Andersson JL, Skare S. Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. Neuroreport 2001, 12(10):2251-2254. 10.1097/00001756-200107200-00041, 11447344.
25. Bartzokis G, Altshuler L. Reduced intracortical myelination in schizophrenia. Am J Psychiatry 2005, 162(6):1229-1230.
26. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302. 10.1002/ana.22366, 3084507, 21387374.
27. APA DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revised 2000, Washington, DC: American Psychiatric Association, APA.
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452. 10.1212/WNL.33.11.1444, 6685237.
29. Kay SR, Opler LA, Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 1986, 149:439-448. 10.1192/bjp.149.4.439, 3814927.
30. Simeoni MC, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J. Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler 2008, 14(2):219-230.
31. Auquier P, Simeoni MC, Sapin C, Reine G, Aghababian V, Cramer J, Lancon C. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr Res 2003, 63(1-2):137-149.
32. Boyer L, Simeoni MC, Loundou A, D'Amato T, Reine G, Lancon C, Auquier P. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res 2011, 121(1-3):241-250.
33. Jensen AR. Scoring the stroop test. Acta Psychol (Amst) 1965, 24(5):398-408.
34. Bowie CR, Harvey PD. Administration and interpretation of the trail making test. Nat Protoc 2006, 1(5):2277-2281. 10.1038/nprot.2006.390, 17406468.
35. Van der Linden M, Coyette F, Poitrenaud J, Kalafat M, Calicis F, Wyns C, Adam S. L'épreuve de rappel libre, rappel indicé à 16 items. L'évaluation des troubles de la mémoire Présentation de quatre tests de mémoire épisodique et étalonnage 2004, 25. Marseille, France, Solal.
36. Wechsler D. WMS-R Echelle clinique de Mémoire de Wechsler-Révisée. 1991, Paris, France, Les Editions du Centre de Psychologie Appliquée.
37. Godefroy O. et le Groupe de Reflexion pour l'Evaluation des Fonctions EXécutives (GREFEX). Fonctions exécutives et pathologies neurologiques et psychiatriques. Evaluation en pratique clinique, Solal edn 2008, Marseille, France: Collection Neuropsychologique.
38. Ware JE, Harris WJ, Gandek B, Rogers BW. MAP-R for Windows: Multitrait-Multi-Item Analysis Program - Revised User's Guide 1997, Boston: Health Assessment Lab.
39. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16:297-334.
40. Wright BD, Stone MH. Best test design: Rasch measurement 1979, Chicago: Mesa press.
41. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003, 74(4):443-446. 10.1136/jnnp.74.4.443, 1738365, 12640060.
42. Braw Y, Bloch Y, Mendelovich S, Ratzoni G, Gal G, Harari H, Tripto A, Levkovitz Y. Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophr Bull 2008, 34(3):544-554. 2632422, 17984299.
43. Zakzanis KK. Distinct neurocognitive profiles in multiple sclerosis subtypes. Arch Clin Neuropsychol 2000, 15(2):115-136. 10.1016/S0887-6177(98)00157-7, 14590556.
44. Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 1997, 120(Pt 2):289-297.
45. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008, 31(7):361-370. 10.1016/j.tins.2008.04.001, 2486416, 18538868.
46. Baumstarck K, Pelletier J, Aghababian V, Reuter F, Klemina I, Berbis J, Loundou A, Auquier P. Is the concept of quality of life relevant for multiple sclerosis patients with cognitive impairment? Preliminary results of a cross-sectional study. Plos ONE 2012, 7(1):e30627. doi:30610.31371/journal.pone.0030627, 10.1371/journal.pone.0030627, 3264575, 22292002.
47. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991, 41(5):685-691. 10.1212/WNL.41.5.685, 2027484.
48. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006, 12(4):549-558.
49. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008, 7(12):1139-1151. 10.1016/S1474-4422(08)70259-X, 19007738.
50. Benito-Leon J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002, 9(5):497-502. 10.1046/j.1468-1331.2002.00450.x, 12220381.
51. Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C. European validation of a standardized clinical description of multiple sclerosis. J Neurol 2004, 251(12):1472-1480. 10.1007/s00415-004-0567-0, 15645346.
52. Bebbington PE, Angermeyer M, Azorin JM, Brugha T, Kilian R, Johnson S, Toumi M, Kornfeld A. The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol 2005, 40(9):707-717. 10.1007/s00127-005-0955-5, 16151597.
53. DeLuca J, Barbieri-Berger S, Johnson SK. The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. J Clin Exp Neuropsychol 1994, 16(2):183-189. 10.1080/01688639408402629, 8021305.
54. Hughes C, Kumari V, Soni W, Das M, Binneman B, Drozd S, O'Neil S, Mathew V, Sharma T. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 2003, 59(2-3):137-146.
55. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007, 64(5):532-542. 10.1001/archpsyc.64.5.532, 17485605.
56. Achiron A, Barak Y. Cognitive changes in early MS: a call for a common framework. J Neurol Sci 2006, 245(1-2):47-51.
57. Arnett PA, Randolph JJ. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006, 77(5):606-610. 10.1136/jnnp.2004.047712, 2117462, 16614019.
58. Debouverie M, Pittion-Vouyovitch S, Brissart H, Guillemin F. Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosis. J Neurol 2008, 255(5):633-636. 10.1007/s00415-008-0761-6, 18217185.
59. Oken BS, Flegal K, Zajdel D, Kishiyama SS, Lovera J, Bagert B, Bourdette DN. Cognition and fatigue in multiple sclerosis: potential effects of medications with central nervous system activity. J Rehabil Res Dev 2006, 43(1):83-90. 10.1682/JRRD.2004.11.0148, 16847774.